Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature
Open Access
- 1 January 2009
- journal article
- review article
- Published by Springer Science and Business Media LLC in Journal of Ovarian Research
- Vol. 2 (1), 13-20
- https://doi.org/10.1186/1757-2215-2-13
Abstract
CA125 is the gold standard tumor marker in ovarian cancer. Serum level of CA125 is used to monitor response to chemotherapy, relapse, and disease progression in ovarian cancer patients. Thus, it is reasonable to investigate whether CA125 may have utility as a prognostic indicator as well in ovarian cancer. A large number of epidemiological studies have been carried out to this effect. This review summarizes all available epidemiological literature on the association between CA125 levels and survival in ovarian cancer. To place these studies in context, we provide some background information on CA125 and its role in ovarian cancer.Keywords
This publication has 79 references indexed in Scilit:
- Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: A French multicentric studyGynecologic Oncology, 2008
- CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients: From The Danish “MALOVA” Ovarian Cancer StudyGynecologic Oncology, 2007
- Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcomeAnnals Of Oncology, 2007
- Biomarkers of ovarian tumoursEuropean Journal Of Cancer, 2004
- Calculation of the Risk of Ovarian Cancer From Serial CA-125 Values for Preclinical Detection in Postmenopausal WomenJournal of Clinical Oncology, 2003
- CA 125 kinetics: A cost-effective clinical tool to evaluate clinical trial outcomes in the 1990sAmerican Journal of Obstetrics and Gynecology, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Early serum CA125 response and outcome in epithelial ovarian cancerEuropean Journal of Cancer and Clinical Oncology, 1990
- CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancerAmerican Journal of Obstetrics and Gynecology, 1989
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983